Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2011 - At today's Annual General Meeting
of Actelion Ltd (SIX: ATLN), held in Basel Switzerland, shareholders voted on a
number of resolutions put forward by the Company's Board.
The meeting was attended by 339 shareholders, representing 56'756'369 shares or
43.31% of the total outstanding shares.
On behalf of the Board and all employees of Actelion, the Chairman of the Board,
Jean-Pierre Garnier, thanked the departing Board member and long-serving
Chairman of Actelion, Robert C. Cawthorn for his services.
Jean-Pierre Garnier, Chairman of the Board of Directors at Actelion, commented:
"When Robert Cawthorn was elected as Chairman of Actelion, he brought with him
an incredible amount of experience in life science."
Jean-Pierre Garnier concluded: "Two distinguishing features have characterized
Rob's leadership as Chairman: First, and foremost, his strategic vision on how
to transform innovation into a successful global business opportunity. Secondly,
he made himself available to management to share his experience, not only as
Chairman but also as coach and mentor. Rob's unwavering commitment to the
company and shareholders earned the respect of all of us."
The shareholders approved the Business Report consisting of the Annual Report,
the Annual Statutory Accounts and the Consolidated Accounts for the year 2011.
A proposal by the Board to distribute as a dividend, out of legal reserve
originating from capital contribution, in the amount of CHF 0.80 per registered
share was passed by the shareholders.
Actelion's shareholders endorsed the Compensation Report through a non-binding
consultative vote.
The shareholders granted discharge to all members of the Board of Directors and
of Senior Management.
A proposal by the Board to approve the reduction of the share capital by means
of cancellation of the corresponding number of repurchased shares, as well as
the amendment of the respective provision in the Company's Articles of
Association, was passed by the shareholders.
Actelion's shareholders voted to re-elect Mr. Michael Jacobi to the Board for a
term of three years.
The shareholders also voted to elect a new Director, Prof. Dr. Peter Gruss, to
the Board for a term of three years.
Following the AGM, Actelion's Board comprises a total of ten members: Jean-
Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel,
Carl Feldbaum, Peter Gruss, Werner Henrich, Michael Jacobi, Armin Kessler, and
Jean Malo.
Finally, the shareholders confirmed Ernst & Young as the Company's statutory
auditors for the year 2012.
###
Notes to the Editor
About Professor Gruss
Peter Gruss has been President of the Max Planck Society since 2002. He became a
Scientific Member of the Max Planck Society in 1986, when he was appointed as
Director at the Max Planck Institute for Biophysical Chemistry in Göttingen. He
earned his PhD in biology at the University of Heidelberg and is honorary
professor at the University of Göttingen.
Peter Gruss began his scientific career as a research assistant at the Institute
for Virus Research in Heidelberg in 1977. From there, he moved on to the
National Institutes of Health in Bethesda, Maryland, initially as a post-doc
associate, and later as an expert consultant. In 1982, he was appointed as
Professor at the Institute for Microbiology at the University of Heidelberg.
Over the years, he has received several honors, including the Leibniz Prize, the
Louis-Jeantet Prize for Medicine, the German Prize for Technology and Innovation
by the President of the Federal Republic of Germany, the Lower Saxony State
Prize, as well as the German Federal Cross of Merit.
As President of the Max Planck Society, Peter Gruss holds numerous offices and
functions. Among others, he is a member of the Senates of the Alliance of
Scientific Organizations in Germany, the German Research Foundation (DFG), the
German National Academy of Sciences Leopoldina, as well as of acatech, the
German Academy of Science and Engineering. In addition, he is member of the
Supervisory Boards of Siemens AG and Munich RE, as well as of the Advisory Board
of Deloitte. He was appointed as a member of the "Innovation Dialogue" of the
Federal Chancellery by Angela Merkel.
About the Max Planck Society
The Max Planck Society is Germany's most successful research organization. Since
its establishment in 1948, no fewer than 17 Nobel laureates have emerged from
the ranks of its scientists, putting it on a par with the best and most
prestigious research institutions worldwide. The more than 13,000 publications
each year in internationally renowned scientific journals are proof of the
outstanding research work conducted at Max Planck Institutes -many of those
articles are among the most-cited publications in their relevant fields.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
Press Release PDF:
http://hugin.info/131801/R/1608896/510767.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1608896]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2012 - 06:55 Uhr
Sprache: Deutsch
News-ID 1110824
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Allschwil
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
